Biohaven Ltd. Operating Income
Biohaven Ltd. (BHVN) reported Operating Income of -$124.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-10
- Biohaven Ltd. operating income (loss) for the quarter ending 2026-06-30 was -$124.90M.
- Biohaven Ltd. operating income (loss) for the quarter ending 2026-03-31 was -$130.43M.
- Biohaven Ltd. operating income (loss) for the quarter ending 2025-12-31 was -$142.73M.
- Biohaven Ltd. operating income (loss) for the quarter ending 2025-09-30 was -$169.38M.
- Biohaven Ltd. operating income (loss) for fiscal 2025 was -$745.38M.
- Biohaven Ltd. operating income (loss) for fiscal 2024 was -$885.11M.
- Biohaven Ltd. operating income (loss) for fiscal 2023 was -$436.05M.
- Biohaven Ltd. operating income (loss) for fiscal 2022 was -$567.93M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$124.90M 10-Q · filed 2026-08-10 | -$255.33M 10-Q · filed 2026-08-10 | -$398.06M derived: sum of 3 quarters · filed 2026-08-10 | -$567.44M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$130.43M 10-Q · filed 2026-05-04 | -$273.16M derived: sum of 2 quarters · filed 2026-05-04 | -$442.54M derived: sum of 3 quarters · filed 2026-05-04 | -$654.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$142.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$312.12M derived: sum of 2 quarters · filed 2026-03-02 | -$523.82M derived: sum of 3 quarters · filed 2026-08-10 | -$745.38M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$169.38M 10-Q · filed 2025-11-10 | -$381.08M derived: sum of 2 quarters · filed 2026-08-10 | -$602.64M 10-Q · filed 2025-11-10 | -$792.58M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$211.70M 10-Q · filed 2026-08-10 | -$433.26M 10-Q · filed 2026-08-10 | -$623.19M derived: sum of 3 quarters · filed 2026-08-10 | -$801.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$221.56M 10-Q · filed 2026-05-04 | -$411.49M derived: sum of 2 quarters · filed 2026-05-04 | -$589.66M derived: sum of 3 quarters · filed 2026-05-04 | -$923.43M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$189.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$368.10M derived: sum of 2 quarters · filed 2026-03-02 | -$701.87M derived: sum of 3 quarters · filed 2026-03-02 | -$885.11M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$178.17M 10-Q · filed 2025-11-10 | -$511.94M derived: sum of 2 quarters · filed 2025-11-10 | -$695.18M 10-Q · filed 2025-11-10 | -$848.89M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$333.77M 10-Q · filed 2025-08-11 | -$517.01M 10-Q · filed 2025-08-11 | -$670.72M derived: sum of 3 quarters · filed 2026-03-02 | -$781.27M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$183.24M 10-Q · filed 2025-05-12 | -$336.95M derived: sum of 2 quarters · filed 2026-03-02 | -$447.50M derived: sum of 3 quarters · filed 2026-03-02 | -$541.51M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$153.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$264.26M derived: sum of 2 quarters · filed 2026-03-02 | -$358.27M derived: sum of 3 quarters · filed 2026-03-02 | -$436.05M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$110.55M 10-Q · filed 2024-11-12 | -$204.56M derived: sum of 2 quarters · filed 2024-11-12 | -$282.34M 10-Q · filed 2024-11-12 | -$495.75M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$94.01M 10-Q · filed 2024-08-09 | -$171.79M 10-Q · filed 2024-08-09 | -$385.20M derived: sum of 3 quarters · filed 2025-03-03 | -$452.84M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$77.78M 10-Q · filed 2024-05-09 | -$291.19M derived: sum of 2 quarters · filed 2025-03-03 | -$358.83M derived: sum of 3 quarters · filed 2025-03-03 | -$555.94M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$213.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$281.05M derived: sum of 2 quarters · filed 2025-03-03 | -$478.16M derived: sum of 3 quarters · filed 2025-03-03 | -$567.93M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$67.64M 10-Q · filed 2023-11-14 | -$264.75M derived: sum of 2 quarters · filed 2023-11-14 | -$354.52M 10-Q · filed 2023-11-14 | -$405.40M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$197.11M 10-Q · filed 2023-07-31 | -$286.88M 10-Q · filed 2023-07-31 | -$337.77M derived: sum of 3 quarters · filed 2024-02-29 | -$393.26M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$89.77M 10-Q · filed 2023-05-12 | -$140.66M derived: sum of 2 quarters · filed 2024-02-29 | -$196.15M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | -$50.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$106.38M derived: sum of 2 quarters · filed 2024-02-29 | -$218.90M 10-K · filed 2024-02-29 | |
| 2021-09-30 | -$55.49M 10-Q · filed 2022-11-09 | -$168.02M 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | -$114.51M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |